1Department of Biochemistry, University of Allahabad, Allahabad, (UP), INDIA.
2Department of Microbiology, Cancer Hospital & Research Institute, Gwalior, (MP), INDIA.
**E-mail: nagendranathmishra@yahoo.co.in
*(Present address), Department of Biotechnology, JM Institute of Engineering and Technology, Radaur-135133, Yamunanagar, (Haryana), INDIA.
Azole anti-fungal agents, especially fluconazole, have been used widely to treat candidiasis in immunocompromised individuals. We investigated the drug efflux and mechanism in azole-resistant and sensitive strains of Candida albicans using rhodamine 6G (R6G). No significant difference in R6G uptake was observed between azole-resistant and sensitive strains incubated in glucose-free media. However, significantly higher R6G efflux was noted in the azole-resistant strains when glucose was added compared with that in the sensitive strains. Our data also suggest that measurement of intracellular accumulation of R6G is a useful method for identification of azole–resistant strains due to CDR1-expressed drug efflux pump.
Azole resistance, AIDS/HIV, diabetic and burn patients, rhodamine6G (R6G) efflux
